 |
|
Intravenous Recombinant Tissue-Type Plasminogen Activator Thrombolysis in Treatment of Central Retinal Artery Occlusion
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The natural history of untreated central retinal artery occlusion (CRAO)
implies a high risk of permanent blindness.1-2
The favorable outcome of intravenous thrombolysis in stroke treatment prompted
us to develop an Institutional Review Board–approved pilot study of
acute CRAO treatment with intravenous thrombolysis. We describe our experience
with 12 patients with acute CRAO who were treated with recombinant tissue-type
plasminogen activator (rtPA), following the protocol used in the national
acute stroke trial.3
Patients and Methods
From October 1998 through October 2000, patients who were diagnosed
with acute CRAO or ophthalmic artery occlusion, and who experienced visual
loss within the preceding 24 hours, were referred as candidates for thrombolysis.
A protocol ophthalmologist (C.R., Parashos Lagouros, MD, or Martha Willi,
MD) confirmed the diagnosis of CRAO. Snellen chart visual acuity and intraocular
pressure were tested. If intraocular pressure was more than 12 mm Hg, an ophthalmologist
(C.R., Parashos Lagouros, or Martha Willi, MD) performed an . . . [Full Text of this Article] Results Comment Corresponding author and reprints: Jorge C. Kattah, MD, Department
of Neurology, University of Illinois College of Medicine at Peoria, OSF Saint
Francis Medical Center, 530 NE Glen Oak Ave, Peoria, IL 61637 (e-mail: kattahj@uic.edu).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Intra-arterial thrombolysis for central retinal artery occlusion
Hayreh
Br. J. Ophthalmol. 2008;92:585-587.
FULL TEXT
Intra-arterial thrombolysis for central retinal artery occlusion: a systematic review
Noble et al.
Br. J. Ophthalmol. 2008;92:588-593.
ABSTRACT
| FULL TEXT
|
